Academic Heart

AURORA Trial Flurpiridaz F-18 PET vs Tc-99 SPECT for CAD In @JACCJournals 👀rb.gy/ksy28 F-18 assoc with: 🤎⬆️ sensitivity 🧡Equal specificity 💛⬆️ image quality 💚⬆️ diagnostic certainty 💙⬇️radiation exposure F-18 half-life = 110 min permits exercise stress

Image of the week From @Bertolin_Car AV Papillary Fibroelastoma

CUFF(SZ) Trial Effect of Cuff Size on the Accuracy of BP Readings From @JAMA_current @JAMAInternalMed 👀shorturl.at/tCES8 Wrong cuff size can greatly affect accuracy of BP measurements.

SURMOUNT-3 Trial Tirzepatide v placebo after lifestyle intervention In @NatureMedicine 👀rb.gy/zu6mv All lost 5% weight with lifestyle bf randomization Then: 💚Tirz = 18.4% weight loss 🤎Placebo = 3.3% weight gain

Adherence to CPAP Treatment and Risk of Recurrent CV Events: Meta-Analysis 💤 From @JAMA_current 👀shorturl.at/giwAC Intention-to-treat CPAP does not reduce CV events. 4+ hours of CPAP adherence does reduce CV events by 30% (HR 0.69).

ADAPTABLE: Enteric-Coated ASA v Uncoated ASA Secondary Analysis From @JAMACardio 👀shorturl.at/f0257 Enteric-coated: 💛No diff ischemic events 💙No diff bleeding events The only time to favor one over the other is ACS: use uncoated for rapid absorption.

@MHBeasleyMD @docbhardwaj @priyaumapathi @FudimMarat @mkonstam @JJheart_doc @HFSA @MHBeasleyMD Pls send us what we missed!

Beauty is in the eye of the beholder! On an upcoming #HFBeat check out the interviews ⁦@priyaumapathi⁩ and I conducted with LBCT presenters ⁦@FudimMarat⁩ @mkonstam⁩ and ⁦@JJheart_doc⁩ - each presented a novel HF treatment approach. ⁦@HFSA⁩ #HFSA2023

🔥CV Conference Calendar🔥 shorturl.at/hovyH

TARGET-HTN Trial Phase 2 trial of Lorundrostat versus placebo for HTN From @JAMA_current 💜LDS is aldosterone synthase inhibitor 💙LDS reduced SBP up to 14 mmHg 💚LDS caused rare hyperK shorturl.at/qsvIJ👀

FDA advisory committee voted 9 to 3 in favor of patisiran benefit-risk profile for ATTR-CM Patisiran 🤎FDA-approved for hereditary ATTR w neuropathy 🧡Under eval in APOLLO-B P3 trial for ATTR-CM 💛An IV RNAi that inhibits TTR synthesis 👀shorturl.at/apNO0

DOAC SCORE New tool to predict bleeding risk among AFib patients on DOACs. In @CircAHA 👀shorturl.at/jlFHM 🤎10 variables 🧡Performed better than HAS-BLED 💛Awaiting online calculator #CardioTwitter #ACCFIT

Muvalaplin, an oral small molecule inhibitor of Lp(a) formation: Phase 1 trial In @JAMA_current 👀shorturl.at/hstF6 💚Reduced Lp(a) up to 60% 💙No adverse effects Lp(a) is 🔥 target to ⬇️ ASCVD and AS based on observational data. No Lp(a) therapy yet FDA-approved.

MULTISTARS AMI Trial Timing of complete revasc w multivessel PCI for AMI From #esccongress2023 In @NEJM 👀shorturl.at/prtxz Complete revasc at time of culprit revasc was better than staging non-culprit revasc in 19-45 day window

Outcomes of Repeat TAVR with Balloon Expandable Valves In @TheLancet Largest registry study shows redo-TAVR is safe and effective with 1-yr follow up. Redo compared to index TAVR: 💛No diff 1-yr death 🧡No diff rehosp 🤎1-year MG 15 v 12 mmHg 👀shorturl.at/bcju5

LODESTAR Trial Rosuvastatin v atorvastatin 🥊 From #esccongress2023 No simultaneous publication Rosuvastatin = ❤️Lower LDL 🧡No diff death 💛No diff AMI 💚More diabetes 💙More cataracts From ACC:

ECLS-SHOCK Trial From #esccongress2023 In @NEJM 👀shorturl.at/GLNR8 VA-ECMO in AMI-related shock: 💛No diff mortality 🧡Increased bleeding Same as: 💙IABP SHOCK II Trial (IABP) 💚IMPRESS Trial (Impella)

Image of the week Quadricuspid Aortic Valve #WhyCMR

🌟Cardiology Conference Calendar🌟 ESC Congress is over! What's up next? 👀rb.gy/potkh

Image of the week rb.gy/potkh 👀LAA thrombus

Peripheral Admin of Norepi Prospective observational study From @accpchest 👀rb.gy/gvevk 635 patients: 💙20% received for 24+ hrs 💚51% avoided central line 💛5% had extravasation events Peripheral NE for short term is safe as bridge to CVC or to avoid CVC